Femara

Femara is a new drug produced for the cure of advanced breast cancer in women. Femara is the second in a novel class of third-generation selective oral aromatase inhibitors. It works by stopping the enzyme aromatase, then blocking the making of estrogen. Femara (letrozole tablets) was well before across all studies in first-line and second-line metastatic breast cancer, adjuvant healing, as well as comprehensive adjuvant treatment in women who have taken preceding adjuvant tamoxifen treatment. Normally, the observed unpleasant side effects are serene or moderate in nature. Femara is used with other medications to treat breast cancer in women who have reached menopause. Femara may also be used for purposes other than those described here. Femara stops the use of estrogen by certain types of breast cancer that need estrogen to grow.

You should not take Femara if you are pregnant as it may cause fatal harm. You must be postmenopausal to take Femara. As with any medicine, side effects are probable with Femara (letrozole); however, not everyone who takes the drug will experience side effects. Some women resorted tiredness and faintness with Femara. Until you know how if affects you, use prudence before driving or operating machinery. Some patients taking Femara had a boost in cholesterol. Extra record is required to find out the risk of bone fracture related to long term use of Femara. In the adjuvant setting, usually reported side effects are normally serene to moderate. Side effects that are similar between Femara and tamoxifen include night sweats, weight gain, nausea, and fatigue. Side effects seen more frequently with tamoxifen versus Femara were hot flashes and vaginal bleeding.



Women for whom Clomid has not worked may use Femara for infertility. Studies have exposed that Femara (a drug approved to treat breast cancer in postmenopausal women) is at least as effective as Clomid when used to stimulate ovulation. Healthcare providers may also use Femara for infertility as a means of keeping away from the problems with cervical mucus and uterine lining that can happen with Clomid. A number of patients, who were identified with hormone-receptor positivie, initial breast cancer and who have not developed metastatic breast cancer, are starting to use Femara (letrozole) rather than Tamoxifen (nolvadex) as a prophylactic precaution against reappearance. The producer of Femara, Novartis, presently has clinical trials in place to evaluate these two medications in the basic setting. However, the current trials comprise only patients diagnosed at Stages I, II, and IIIA. After two years of record, early results from the BIG 1-98 study demonstrated that post-menopausal women with hormone-receptor-positive breast cancer who took Femara had a considerably lower risk of return and increased rate of disease-free endurance as compared to women who took tamoxifen.